European Journal of Cancer 1995: Vol 31A Index & Table of Contents

65 Pages·1995·12.1 MB·English

European Journal
of Cancer
Volume 31A, 1995
List of Contents and Author Index
© PERGAMON
European Journal of Cancer
FOUNDING EDITOR: Henri Tagnon, Brussels, Belgium
PAST EDITOR: Michael Peckham, London, UK
EDITOR-IN-CHIEF: Hans-Jérg Senn, Interdisciplinary Oncology Centre, Department of Medicine C, Kantonsspital CH-9007,
St Gallen, Switzerland
EDITOR EXPERIMENTAL Ian Hart, Richard Dimbleby Department of Cancer Research, St Thomas’ Hospital, Lambeth Palace Road,
ONCOLOGY: London SE1 7EH, UK
ASSOCIATE EDITORS: Michel Bolla, Grenoble, France
Jan Willem Coebergh, Eindhoven, The Netherlands
Daniel C. Ihde, St. Louis, USA
Silvio Monfardini, Aviano, Italy
Jon Pritchard, London, UK
Peter M. Schlag, Berlin, Germany
EDITORIAL OFFICE: European Journal of Cancer, British Postgraduate Medical Federation, 33 Millman Street,
London WCIN 3E]J, UK. Tel: [phone]; Fax: [phone]
- London Delphine Purves, Scientific Editor
Brad Timms, Editorial Assistant
- St Gallen Manfred Lehnert, Assistant Editor (Translational Research)
Beat Thiirlimann, Assistant Editor (Clinical Oncology)
Armanda Schiess, Editorial Secretary
European Journal of Cancer Part B: Oral Oncology
Crispian Scully, Eastman Dental Institute for Oral Healthcare Sciences, 256 Grays Inn Road,
London WC1X 8LD, UK
EDITORIAL CONSULTANTS
M. Aapro /taly B. Gusterson UK H.T. Mouridsen Denmark
P. Alberto Switzerland J.L. Habrand France M. Namer France
K. Antman USA C.H. Heldin Sweden D.R. Newell UK
J.P. Armand France C. Henderson USA G. Peters The Netherlands
H. Bartelink The Netherlands G. Henze Germany W.P. Peters USA
M. Baum UK R. Herrmann Switzerland K. Pritchard-Jones UK
W. Birchmeier Germany B. Hirt Switzerland D. Raghavan USA
W. Bodmer UK J.C. Horiot France G. Ries Switzerland
G. Bonadonna /taly C.H. Huber Germany C.M. Rudenstam Sweden
P. Boyle /taly H. Huber Austria S.E. Salmon USA
G. Canellos USA R. Jakesz Austria R. Sauer Germany
A. Carbone /taly V.C. Jordon USA J.H. Scarffe UK
M. Castiglione Switzerland W.F. Jungi Switzerland HJ. Schmoll Germany
J. Collard The Netherlands M. Kasler Hungary R. Souhami UK
A. Costa /taly S.B. Kaye UK P. Steeg USA
J. Cuzick UK L. Kelland UK C.A. Stiller UK
Y. De Clerk USA J. Klastersky Belgium I. Tannock Canada
M. D’Incalci Jtaly P. Kleihues France J.P. Thierry France
D.-I. W. Diichting Germany F. Levi Switzerland N. Trapeznikov Russia
J. Estapé Spain M.E. Lippmann USA E. van der Schueren Belgium
I. Fentiman UK H. Ludwig Austria J. van Dongen The Netherlands
B. Fisher USA P. Maguire UK C. van Kalken The Netherlands
G. Gahrton Sweden J.G. McVie UK A.T. van Oosterom Belgium
G. Gasparini /taly R. Mertelsmann Germany U. Veronesi /taly
R. Giavazzi Italy F. Meunier Belgium J. Verweij The Netherlands
A. Glaus Switzerland U. Metzger Switzerland P.A. Voiite The Netherlands
D.M. Green USA C. Misset France H.P. Wagner Switzerland
P. Greenwald USA J.-L. Misset France
NEWS COMMITTEE
F. Meunier (Chair), EORTC, Brussels P. Pritchard, FECS, Brussels
A. Costa, ESO, Milan C. van Kalken, NDDO, Brussels
M. Price, EACR, Nottingham T. Reynolds, NCI, London
Elsevier Science Tanwen Evans, Production Editor
LIST OF CONTENTS
NUMBER|
Announcement
Paediatric oncology
M. Peckham
Comments and
Critique
Outpatient treatment of febrile neutropenic patients with cancer
E.B. Rubenstein and K.V.I. Rolston
Adjuvant radiotherapy following radical prostatectomy—results of 56 patients
T. Wiegel, M. Bressel and U.M. Carl
Volume adjustment for intermediate prostate-specific antigen values in a screening population
Chr.H. Bangma, D.E. Grobbee and F .H. Schroder
Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients
M. Clavel, 7. Bonneterre, H. d’Allens, J.-M. Paillarse and the French Ondansetron Study Group
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and
leucovorin in patients with unresectable or metastatic colorectal carcinoma
S.D. Heys, O. Eremn, E.M. Ruggeri, F. Pen, H. Rainer; R. Oskam, R.A. de Peuter, P.A. Palmer and
C.R. Franks
Assessment of anthracycline-related myocardial adrenergic derangement by {!”°I]|metaiodobenzylguanidine 26
scintigraphy
R.A. Valdés Olmos, W.W. ten Bokkel Huinink, R.F .A. ten Hoeve, H. van Tinteren, P.F . Bruning, B. van Vives
and C.A. Hoefnagel
Post-irradiation soft tissue sarcoma
C. Bloechle, M. Petper, R. Schwarz, S. Schroeder and C. Zormg
Combination of cisplatin and interferon-c.2a (Roferon*-A) in patients with non-small cell lung cancer
(NSCLC). An open phase IT multicentre study
V. Kataja and A. Yap for The NSCLC Collaborative Study Group
Hepatic resection for metastases from colorectal carcinoma — a survival analysis
G.R. Fatzko, P.H. Lisborg, H.M.Stettner and M.H. Klimpfinger
A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide 46
chemotherapy
S. Tafuto, G. Abate, P. D’Andrea, I. Silvestri, P. Marcolin, C. Volta, A. Monteverde, S. Colombi, S. Andorno
and M. Aghetta
List of Contents
Type I insulin-like growth factor receptors in human colorectal cancer
A. Adens, J.-P. Peyrat, B. Hecquet, A. Delobelle, G. Depadt, P. Quandalle,7 .Bo nneterre and A. Demaille
A recent increase in the incidence of prostatic carcinoma in a French population: role of ultrasonography
and prostatic specific antigen
F. Ménégoz, M.Colonna, C. Exbrayat, M. Mousseau, H. Orfeuvre and R. Schaerer
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled
normothermic perfusion for recurrent melanoma of the extremities
J.M. Klaase, B.B.R. Kroon, A.M.M. Eggermont, A.N. van Geel, H. Schraffordt Koops,7 . Ol dhoff,
D. Liénard, F 7. Lejeune, R. Berkel, H.R. Franklin and A.A.M. Hart
Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?
P. Pfeiffer, P. Sorensen and C. Rose
Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients
A. V. Boddy, M. Proctor, D. Simmonds, M. 7. Lind and7 .R . Idle
Incident cases of primary liver cancer (PLC): proposal for the use of a standardised method in case-definition 77
S. Rodella, F. Donato, R. Chiesa, C. Picoco, L. Fiore Donan and G. Nardi
Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions 79
P. Ferroni, L. Len, F. Guadagm, F. Martim, F. D’Agostno, A. Spila, G.M. Pontien and P.P. Gazzaniga
Radiosensitivity of multicellular tumour spheroids obtained from human ovarian cancers
G. Griffon, C. Marchal, 7. -L. Merlin, S. Marchal, R.M. Parache and P. Bey
Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines 92
in vitro
U. Vanhoefer, A. Harstrick, H. Wilke, N. Schleucher, H. Walles,¥ .S chroder and S. Seeber
Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats 97
P. Daneryd, L. Hafstrém, E. Svanberg and I. Karlberg
Disregulation of urokinase plasminogen activator gene in breast cancer 103
A.L. Hubbard,7 .L auder, R.A. Hawkins and TJ. Anderson
Cytidine triphosphate (CTP) synthetase activity during cell cycle progression in normal and malignant 108
T-lymphocytic cells
A. A. van den Berg, H. van Lenthe, .B.A. Kipp, D. de Korte, A.B.P. van Kuilenburg and A.H. van Genmp
Feature Articles
Offering choice of treatment to patients with cancer. A review based on a symposium held at the 10th Annual 112
Conference of The British Psychosocial Oncology Group, December 1993
M.A. Richards, A.J. Ramirez, L.F . Degner, L.}. Fallowfield, E.7. Maher andJ .N euberger
Apoptosis in the embryo and tumorigenesis
G. Prindull
List of Contents
News
Letters
Elevated levels of p53 protein in adrenocortical carcinomas from Costa Rica
A. Hildesheim, R. Herre7.rJ oohn,son , C. Brat, K. Bhana, I.T. Magrath and7. F. Fraumenfi r
Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for metastatic soft tissue
sarcoma
P.A. Vasey, D.F. Dunlop and W.P. Steward
Failure to increase 5-fluorouracil activity with interferon-c2a in the treatment of advanced colorectal cancer
A. Martom, L. Bidin, C. Zamagm, A. Cricca and F .. Pannuti
Absence of microsatellite instability in thyroid carcinomas
F. Vermgho, M. Schlumberger, V. Lazar, I. Lefreré and B. Bressac
D2 prostate cancer—half dosage of the LHRH-agonists is sufficient for complete androgen deprivation
A. Fungwirth, D. Mack and7 .F rick
High serum level of CA125 in malignant peritoneal mesothelioma
H. Simsek, A. Kadayifci and E. Okan
Phase II study of cystemustine in advanced renal cancer
4. Chauvergne, P. Kerbrat, A. Adems, P. Chollet, P. Fargeot, E. Pujade-Lauraine, V. Dieras,
F.C. Madelmont, M.A. Lentz, C. Toulouse and B. Chevallier
Cladribine and tumour lysis syndrome
S. Anchisi, G.B. Zultan, P.Y. Dietrich and P.. Alberto
NUMBER 2
Comments and
Critique
Constitutional aplastica naemia: a new concerted action for European Fanconi anaemia research (EUFAR)
E. Gluckman and H. Foenje
“Megatherapy” for advanced neuroblastoma—rationale and role
¥. Prichard
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue
goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer
W. Fonat, M. Kaufmann, R.W. Blamey, A. Howell, 7.P. Collins, A. Coates, W. Etermann, F . Fanicke,
B. Njordenskold7,. F. Forbes and G.J.C.M. Kolvenbag
Vv
List of Contents
Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell 143
carcinoma of the bladder. A prospective randomised study
4. Flamm, G. Donner, S. Oberleitner, R. Hausmann and L. Havelec
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and 146
interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German
myeloma treatment group
D. Peest, H. Deicher, R. Coldewey, R. Leo, R. Bartl, H. Bartels, H.}. Braun, W. Fett, 7.7. Fischer, B. Gobel,
P. Harms, R. Henke, L. Hoffmann, E.D. Kreuser, W.D. Maier, C.R. Meter,J .O ertel, M. Petit, M. Planker,
C. Platzeck, M. Respondek, E. Schafer, K. Schumacher, M. Stennes, W. Stenzinger, C. Tirier, H. Wagner,
HJ. Weh, P. von Wussow andF .W ysk
The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to 152
increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment
of small cell lung cancer
N. Thatcher, H. Anderson, N.M. Bleehen, D.7. Girling, G. Lallemand, D. Machin and R.7. Stephens
on behalf oft he Medical Research Council Lung Cancer Working Party
Psychological reactions in patients with malignant melanoma
Y. Brandberg, E. Mansson-Brahme, U. Ringborg and P.-O. Sjodén
Quality of life in adult cancer patients treated with bone marrow transplantation—a review of the literature
M.7. Hyermstad and S. Kaasa
A randomised study to determine whether routine intravenous magnesium supplements are necessary in
patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil
T.R.J. Evans, C.L. Harper, 1.G. Beveridge, R. Wastnage and J.L. Mans
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with
metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype
G. Fontanini, S. Vignati, D. Bigini, A. Mussi, H. Lucch, C.A. Angeletu, R. Pingitore, S. Pepe, F. Basolo
and G. Bevilacqua
Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of '''In-DTPA octreotide
scintigraphy
E. Bombardier, F. Crippa, I. Cataldo, A. Chiti, E. Seregm, E. Soresi, R. Boffi, G. Invernizzi and
G.L. Buraggi
Treatment of poor prognosis epidemic Kaposi’s sarcoma with doxorubicin, bleomycin, vindesine and
recombinant human granulocyte-monocyte colony stimulating factor (rh GM-CSF)
P.7.M. Bakker, S.A. Danner, C.H.H. ten Napel, FP. Kroon, H.G. Sprenger, R. van Leusen,
P.L. Meenhorst, A. Muusers and C.H.N. Veenhof
The mortality rate oft he province of birth as a risk indicator for lung and stomach cancer mortality among
Genoa residents born in other Italian provinces
M. Ceppi, M. Vercelli, A. Decarli and R. Puntoni
Detection by polymerase chain reaction of BCR/ABL transcripts in myeloproliferative diseases at time of
diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation
C. Bianchi, R. Cairoli, P. Marenco, G. Muti, U. Del Monte and R.A. Perego
vi
List of Contents
Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and
tumour cells and tissues
T. Spasokoukotskaja, E.S.F. Arnér, O. Brosjo, P. Gunvén, G. Fuliusson,7 .L ilemark and S. Eriksson
Formation of cytosine arabinoside-5’-triphosphate in different cultured lymphoblastic leukaemic cells with
reference to their drug sensitivity
U. Kohl, D. Schwabe, E. Montag, S. Bauer, B. Mieth,¥ .C inatl,7 .C inatlFr , E. Rohrbach, M. Mainke,
A. Weifflog, C. Sommerschuh and B. Kornhuber
Primary sequence determination and molecular modelling of the variable region of an antiMUC] mucin
monoclonal antibody
G. Denton, G. M. DaviesM., 7 .S canlon, §. 3.B . Tendlaendr M .R . Price
Clonal dominance between subpopulations of mixed small cell lung cancer xenografts implanted ectopically
in nude mice
K. Aabo, L.L. Vindelgo and M. Spang-Thomsen
Resistance mechanisms determining the in v1tro sensitivity to paclitaxel of tumour cells cultured from
patients with ovarian cancer
B.C. Baguley, E.S. Marshall, J.R. Whittaker, M.C. Dotchin,J .N ixon, M.R. McCrystal, G7. Finlay,
4.H.L. Matthews, K.M. Holdaway and P. van Zijl
Growth regulation by all-trans-retinoic acid and retinoic acid receptor messenger ribonucleic acids
expression in gastric cancer cells
R.-Y. Shyu, S.-Y. Jiang, S.-L. Huang, T.-C. Chang, K.-L. Wu, S.R. Roffler and M.-Y. Yeh
Effects of suramin on human lung cancer cell lines
G.J. Rubio, H.M. Pinedo,7 .V irizuela, 7. van Ark-Oite and G. Giaccone
Multi-modality megatherapy with ['>"I] meta-iodobenzylguanidine, high dose melphalan and total body
irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma
M.N. Gaze, T.E. Wheldon, J.A. O’D onoghue, T.E. Hilduch, S.G. McNee, E. Simpson and A. Barrett
A new '7]-MIBG whole body scan scoring method—application to the prediction of the response of
metastases to induction chemotherapy in stage IV neuroblastoma
N. Ady, ¥.-M. Zucker, B. Asselain, V. Edeline, F. Bonnin,F .M ichon, R. Gongora and L. Manil
A phase I study of human/mouse chimeric anti-ganglioside GD2 antubody ch14. 18 in patients with
neuroblastoma
R. Handgretinger, K. Anderson, P. Lang, R. Dopfer, T. Klingebiel, M. Schrappe, P. Reuland, S. D. Gillies,
R.A. Reisfeld and D. Ntethammer
FeatureArticles
Fanconi anaemia research: current status and prospects
H. Foenje, C. Mathew and E. Gluckman
Quality assurance in breast cancer screening cytology: a review of the literature and a report on the U.K.
national cytology scheme
C.A. Wells
List of Contents
letters
Prognostic factor clustering in breast cancer: biology or chronology?
M. Tubtana-Hulin, K. Hacéne, P.M. Martin and F . Spyratos
Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin
E.W. Pommerenke, H. Sinn and M. Volm
Hereditary breast cancer in 19 females and 2 males: kindred, P.G. 1940
P. Ghadinan, S. Narod, C. Perret, D.M. Lambert,F .La treille, F . Letendre, M. Monté and D. Belanger
Correction
NUMBER 3
Comments and
Critique
Non-specialist units, clinical trials and survival from testicular cancer
C.A. Stiller
Should we still advocate referral to specialist centres for teratoma?
M.. Hughes and S.B. Kaye
Testicular cancer treated in a minor general oncology department
J. Norum, T. Nordgy and E. Wist
Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced
ovarian cancer patients treated with platinum-based chemotherapy
S. Chiara, R. Lionetto, E. Campora, C. Oliva, L. Merlim, P. Bruzzt, R. Rosso and P.F . Conte
for the Gruppo Oncologico Nord Ovest
Value of granulocyte colony stimulating factor in radiotherapy induced neutropenia: clinical and laboratory
studies
M.P. Mac Manus, D. McCormick, A. Trimble and W.P. Abram
Is neuro-ectodermal differentiation of Ewing’s sarcoma of bone associated with an unfavourable prognosis?
Ph. Terner, M. Henry-Amar, TJ. Triche, M.E. Horowitz, M.-7. Terer-Lacombe, 7.5. Miser, TF. Kinsella,
G. Contesso and A. Llombart-Bosch
Different dose regimens of 5-fluorouracil and interferon-c in patients with metastatic colorectal carcinoma
P. Ragnhammar, H. Blomgren, D. Edler, G. Lundell, I. Magnusson and T. Sonnenfeld
Viii
List of Contents
Prognostic parameters in localised melanoma: gender versus anatomical location 320
C.P. Karakousis and D.L. Driscoll
Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors 325
D.7. Oliver and D.M. Ingram
Expression of retinoblastoma gene protein (Rb) in breast-cancer as related to established prognostic factors 329
and survival
T. Pretlainen, P. Lipponen, S. Aaltomaa, M. Eskelinen, V.-M. Kosma and K. Syrjénen
Parathyroid hormone-related protein (PTHrP) in breast cancer and benign breast tissue 334
R.C. Edwards, W.A. Ratcliffe,7 . Walls, 7.M. Morrison, 7.G. Ratcliffe, R. Holder andN .. Bundred
Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostateand 339
benign prostatic hyperplasia
3.M. Wolff, R.N. Stephenson, G.D. Chisholm and F .K. Habib
Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated 342
radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: results of a phase I-II
study by the GOTHA group
P. Alberto, R.O. Mirimanoff, B. Mermillod, S. Leyoraz, H. Nagy-Mignoue, M. Bolla, D. Wellmann, D. Moro
and E. Brambilla
A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme 348
in the city of Florence, Italy
E. Pact, R. Boer, M. Zappa, HJ. deK oning, G.F. van Oortmarssen, E. Crocetti, D. Giorgi, M. Rosselli Del
Turco and7 .D.F . Habbema
Trends in cervical cancer incidence in the district of Florence 354
S. Ciano, S. Cecchini, A. Tossa, G. Grazzini, R. Bonardi, M. Zappa, S. Cart and A. Barchelli
Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin 356
M. Drees, W.M. Dengler, H.R. Hendriks, L.R. Kelland and H.H. Fiebig
Growth factor requirement, oncogene expression and 7P53 mutations of a tumorigenic and a non- 362
tumorigenic subline of the human breast carcinoma cell line, HMT-3909
M.W. Madsen, C. Moyret, C. Theillaendt P .B riand
Prophylaxis and therapy of mouse mammary carcinomas with doxorubicin and vincristine encapsulated in 367
sterically stabilised liposomes
4. Vaage, D. Donovan, T. Loftus, P. Uster andP . Working
Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide 372
4. Stekar, P. Hilgard and T. Klenner
Extracellular matrix proteins inhibit proliferation, upregulate migration and induce morphological changes in375
human glioma cell lines
S. Koochekpour, A. Merzak and G.J. Pilkington
KT-5720 reverses multidrug resistance in variant $49 mouse lymphoma cells transduced with the human 380
MDRI cDNA and in human multidrug-resistant carcinoma cells
H. Galski, P. Lazarovici, M.M. Gottesman, C. Murakata, Y. Matsuda and7 .H ochman
ix
List of Contents
Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of 389
rat glioblastoma cells
Y.-P. Hu, N. Henry-Toulmé and}. Robert
Clonal diversity, measured by heterogeneity of Ig and TCR gene rearrangements, in some acute leukaemias
of childhood is associated with a more aggressive disease
T. Stankovic, J.R. Mann, PJ. Darbyshire and A.M.R. Taylor
Feature Articles
Renal cell carcinoma and interleukin-2: a review
4. Wagstaff, 7.W. Baars, G.-7. Wolbink, K. Hoekman, A.J.M. Eerenberg-Belmer and C.E. Hack
Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe
§.S. Burtles, D.R. Newell, R.E.C. Henrar and T.A. Connors on behalf oft he Cancer Research Campaign
(CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of
Cancer (EORTC) New Drug Development Office
EORTC Receptor
Study Group Report
Steroid receptor distribution in 47 892 breast cancers. A collaborative study of 7E uropean laboratories
S. Romain, C. Lainé Bidron, P.M. Martin, H. Magdelenat on behalf oft he EORTC Receptor Study Group
News
Letters
Resection of a solitary brain metastasis in a patient with small cell lung cancer — long-term survival
R.P. Abratt, M. de Groanod tP. A. Willcox
The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of
plasma insulin-like growth factor-1
R. Toms, F. Pensa, V. Fontana, A. Costa andA .D ecensi
Fotemustine and tamoxifen combination therapy in metastatic malignant melanoma. A phase II study
C.J.A. Punt, J.H. Tytgat, P.A. van Liessum and B. Gerard
Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome
C. Manchy, C. Dumontet, Y. Bastion, C. Rieux, 7.Y. Blay, G. Salles, P. Biron and B. Coiffier
Evidence of responsiveness to chemotherapy in aggressive Rosai-Dorfman disease
M. Colleoni, F. Gaton, A. Perasole, P. Nelli and P. Manente
Effective stimulation of thrombopoiesis with interleukin-3 (IL-3) in chemotherapy-induced
myelosuppression—a case report
C. Schweiger, L. Farber andW . Metnerz
Prospective analysis of the information level of Italian cancer patients 425
A. Veronesi, C. Busato, M.A. Annunziata, M.D. Magni, S. Foladore, M. Zanon, S. Tumolo andS .M onfardini
x